NephCure Welcomes Three Dynamic Leaders to its Board of Directors 

NephCure, a leading nonprofit organization dedicated to finding better treatment options and a cure for rare kidney disease, proudly announces the appointment of three distinguished individuals to its Board of Directors. These additions, Eve Dryer, Barbara S. Gillespie, MD, MMS, FASN, and Reverend Leroy Miles, each bring a wealth of experience and expertise that promises to drive NephCure’s mission forward.

“These three exceptional individuals bring a wealth of experience and unwavering dedication to patient advocacy and community service. They are all deeply committed to supporting those affected by rare kidney disease and we are grateful for their leadership. With their addition to our Board of Directors, our organization is primed to build upon our successes and make an even greater impact in the fight against rare kidney diseases,” NephCure’s Chief Executive Officer, Josh Tarnoff said.

Eve Dryer, an esteemed leader in rare disease patient advocacy and healthcare communications with over 25 years of experience, recently retired from her role as VP of Patient Advocacy at Travere Therapeutics. Throughout her career, she has been a driving force in advancing health literacy and improving outcomes in underserved communities. Formerly, she founded and led Vox Medica’s PR and patient advocacy practices, earning accolades such as five Silver Anvil Awards and recognition in the PharmaVOICE 100. Eve’s dedication extends to her roles on the Board of Sisters Network Inc. and as a past chair of HealthyWomen’s Board of Directors. Her legacy includes championing patient diversity and inclusion initiatives, including her role in founding the Rare Disease Diversity Coalition and Travere’s internal Rare Disease Patient Advisory Council. With impactful endeavors like Teens for Pink (focused on African American breast cancer) and her leadership at a Philadelphia-based healthcare PR agency, Eve continues to be a pivotal figure in healthcare advocacy.

Barbara S. Gillespie, MD, MMS, FASN, is a board-certified adult nephrologist who completed her internal medicine residency at the University of North Carolina (UNC) and nephrology fellowship at Duke University Medical Center. Currently serving as Vice President and Therapeutic Head of Nephrology at Fortrea (formerly Labcorp Drug Development), she supports patient centered clinical development (drugs and devices) and trials for kidney diseases. Dr. Gillespie is also an Adjunct Professor at UNC’s Division of Nephrology and Hypertension, and serves on the boards of Kidney Health Initiative (recent past) and NephroNet (current). She serves on numerous committees and advisory roles, including with the NKF and NephCure, and remains committed to advancing nephrology research to facilitate better patient care.

Reverend Leroy Miles, an accomplished Mental Health Counselor, Certified Health Coach, and Community Health Consultant, has dedicated his career to enhancing public health both in the U.S. and internationally. Through his leadership as an Associate Pastor of Pastoral Care and Counseling at Enon Tabernacle Baptist Church, in Philadelphia, PA, he oversees ministries providing vital support in mental health, HIV/AIDS, anger management, drug and alcohol recovery, surviving sexual abuse, and maternal health— including the recent launch of a doula program addressing racial disparities in Black maternal health. Additionally, Rev. Miles spearheads city-wide charitable initiatives and serves as a Covid-19 testing/vaccination site lead. Rev. Miles’ commitment to health policy improvement is further demonstrated through his board membership with the American Heart Association. A multifaceted individual, he is also a certified anger management educator, martial arts black belt, avid cyclist, and competitor in endurance events like Tough Mudder and Spartan Race.

These three individuals, Eve Dryer, Dr. Gillespie, and Rev. Miles, bring diverse yet complementary expertise and experiences to NephCure. Together, their collective passion and expertise make them a formidable team, capable of driving meaningful change in rare kidney disease healthcare, research, and patient care.

About NephCure:

NephCure’s mission is to empower people with rare, protein-spilling kidney disease to take charge of their health, while leading the revolution in research, new treatments, and care. Founded in 2000 by a group of committed patient parents, NephCure has invested more than $40 million in kidney disease research and helped create a landscape where there are now new treatments and more than 60 interventional drug trials for rare kidney diseases. NephCure is a U.S. tax exempt 501(c)(3) public charity.

Sign up to get NephCure’s latest updates.

This field is for validation purposes and should be left unchanged.